Updated January 30 at 10:30am

MultiCell Technologies updates research results

WOONSOCKET – MultiCell Technologies announced on Aug. 10 its updates on preclinical research results for MCT-465 and MCT-485, the first of a family of prospective cancer therapeutics based on the use of its patented signaling technology. MCT-465 and MCT-485 are being investigated as prospective treatments for primary liver cancer and triple-negative breast cancer. More

To continue reading this article, please do one of the following.



HEALTH CARE

MultiCell Technologies updates research results

Posted:

WOONSOCKET – MultiCell Technologies announced on Aug. 10 its updates on preclinical research results for MCT-465 and MCT-485, the first of a family of prospective cancer therapeutics based on the use of its patented signaling technology. MCT-465 and MCT-485 are being investigated as prospective treatments for primary liver cancer and triple-negative breast cancer.

The latest preclinical results for MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines, according to the company. In contrast, MCT-465 showed no cytotoxicity or anti-proliferative effect, according to the company.

The research results support further mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as novel therapeutic agents as a treatment for hepatocellular carcinoma and other cancers, according to MultiCell Technologies.

Hepatocellular carcinoma is the most common form of primary liver cancer and a leading cause of cancer death. Current pharmacological approaches for treatment have been very limited in their efficacy. •

27~20, 082012 HEALTH CARE NEWS BRIEFS, health services, biotechnology, life sciences, health care, MultiCell Technologies¸, 27~20, issue082012export.pbn

Comments

No comments on this story | Please log in to comment by clicking here
Please log in or register to add your comment
Latest News